[go: up one dir, main page]

WO2003072722A3 - IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY - Google Patents

IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY Download PDF

Info

Publication number
WO2003072722A3
WO2003072722A3 PCT/US2003/005315 US0305315W WO03072722A3 WO 2003072722 A3 WO2003072722 A3 WO 2003072722A3 US 0305315 W US0305315 W US 0305315W WO 03072722 A3 WO03072722 A3 WO 03072722A3
Authority
WO
WIPO (PCT)
Prior art keywords
enhanced stability
immunogenic
hbc chimer
chimer particles
ahbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/005315
Other languages
French (fr)
Other versions
WO2003072722A2 (en
Inventor
Ashley J Birkett
Birgit Peck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apovia Inc
Original Assignee
Apovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apovia Inc filed Critical Apovia Inc
Priority to AU2003213194A priority Critical patent/AU2003213194A1/en
Publication of WO2003072722A2 publication Critical patent/WO2003072722A2/en
Publication of WO2003072722A3 publication Critical patent/WO2003072722A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A chimeric, carboxy-terminal truncated avian hepatitis B virus nucleocapsid protein (AHBc) is disclosed that is engineered for both enhanced stability of self-assembled particles and the display of an immunogenic epitope. The display of the immunogenic epitope is displayed in the immunogenic loop of AHBc, whereas the enhanced stability of self­assembled particles is obtained by the presence of at least one heterologous cysteine residue near the carboxy-terminus of the chimer molecule. Methods of making and using the chimers are also disclosed.
PCT/US2003/005315 2002-02-21 2003-02-21 IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY Ceased WO2003072722A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003213194A AU2003213194A1 (en) 2002-02-21 2003-02-21 IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35912902P 2002-02-21 2002-02-21
US60/359,129 2002-02-21

Publications (2)

Publication Number Publication Date
WO2003072722A2 WO2003072722A2 (en) 2003-09-04
WO2003072722A3 true WO2003072722A3 (en) 2004-07-29

Family

ID=27766042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/005315 Ceased WO2003072722A2 (en) 2002-02-21 2003-02-21 IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY

Country Status (2)

Country Link
AU (1) AU2003213194A1 (en)
WO (1) WO2003072722A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010086743A2 (en) * 2009-02-02 2010-08-05 Chrontech Pharma Ab Compositions and methods that enhance an immune response

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031382A1 (en) * 1997-01-21 1998-07-23 New York University Universal t-cell epitopes for anti-malarial vaccines
US6231864B1 (en) * 1998-02-12 2001-05-15 Immune Complex Corporation Strategically modified hepatitis B core proteins and their derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031382A1 (en) * 1997-01-21 1998-07-23 New York University Universal t-cell epitopes for anti-malarial vaccines
US6231864B1 (en) * 1998-02-12 2001-05-15 Immune Complex Corporation Strategically modified hepatitis B core proteins and their derivatives

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
KRATZ ET AL.: "Native Display of Complete Foreign Protein Domains on the Surface of Hepatitis B Virus Capsids", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 96, March 1999 (1999-03-01), pages 1915 - 1920, XP000910194 *
METZGER ET AL.: "Proline-138 is Essential for the Assembly of Hepatitis B Virus Core Protein", JOURNAL OF GENERAL VIROLOGY, vol. 79, 1998, pages 587 - 590, XP002977292 *
MILICH ET AL.: "Conversion of Poorly Immunogenic Malaria Repeat Sequences into a Highly Immunogenic Vaccine Candidate", VACCINE, vol. 20, 12 December 2001 (2001-12-12), pages 771 - 788, XP004312521 *
NARDIN ET AL.: "Conserved Repetitive Epitope Recognized by CD4+Clones from a Malaria-Immunized Volunteer", SCIENCE, vol. 246, no. 4937, 22 December 1989 (1989-12-22), pages 1603 - 1606, XP002977291 *
PAOLETTI ET AL.: "Preclinical Evaluation of Group B Streptococcal Polysaccharide Conjugate Vaccines Prepared with a Modified Diphtheria Toxin and a Recombinant Duck Hepatitis B Core Antigen", VACCINE, vol. 12, 12 November 2001 (2001-11-12), pages 370 - 376, XP004310142 *
PUMPENS ET AL.: "Hepatitis B Virus Core Particles as Epitope Carriers", INTERVIROLOGY, vol. 38, 1995, pages 63 - 74, XP002903139 *
SCHODEL ET AL.: "Immunity to Malaria Elicited by Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Protein Epitopes", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 180, November 1994 (1994-11-01), pages 1037 - 1046, XP000891465 *
SCHODEL ET AL.: "Structure of Hepatitis B Virus Core and e-Antigen", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 2, 15 January 1993 (1993-01-15), pages 1332 - 1337, XP002928662 *
WASENAUER ET AL.: "A Cysteine and a Hydrophobic Sequence in the Noncleaved Portion of the Pre-C leader peptide Determine the Biophysical Properties of the Secretory Core Protein (HBe protein) of Human Hepatitis B Virus", JOURNAL OF VIROLOGY, vol. 66, no. 9, September 1992 (1992-09-01), pages 5338 - 5346, XP002977293 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform

Also Published As

Publication number Publication date
AU2003213194A8 (en) 2003-09-09
WO2003072722A2 (en) 2003-09-04
AU2003213194A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
WO2002014478A3 (en) IMMUNOGENIC HBc CHIMER PARTICLES HAVING ENHANCED STABILITY
WO2005055957A3 (en) Influenza immunogen and vaccine
WO2004075836A3 (en) STABILIZED HBc CHIMER PARTICLES AS THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS
WO2002013765A3 (en) Malaria immunogen and vaccine
WO2004053091A3 (en) STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
WO2007011904A3 (en) Recombinant flu vaccines
UA85536C2 (en) Viral antigens
PL1648502T3 (en) Hcv vaccines
WO2003072731A3 (en) STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
EP0992580A3 (en) Immunodominant human T-cell epitopes of Hepatitis C virus
DK1294893T3 (en) Modification of hepatitis B core antigen
WO2005073216A3 (en) Hcv ns-3 serine protease inhibitors
DK1294892T3 (en) Aggregation of wild-type and chimeric influenza virus-like particles (VLPs)
WO2003102165A3 (en) IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
WO2009130588A3 (en) Codon-optimzed hepatitis b virus core antigen (hbcag)
WO2004048402A3 (en) A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
WO2009014782A3 (en) Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2003072722A3 (en) IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY
AU2003261977A1 (en) Hbv precore protein capable of forming particles
WO1996035717A3 (en) Soluble, cleavable substrates of the hepatitis c virus protease
WO2002088339A3 (en) Bursal disease virus-like particles
ATE424409T1 (en) CHIMERE HUMAN PAPILLOMA VIRUS 16 L1 PROTEINS CONTAINING A L2 PEPTIDE, VIRUS-LIKE PARTICLES PRODUCED THEREFROM AND METHOD FOR PRODUCING THE PARTICLES
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
WO2005113837A3 (en) Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
WO2008024518A3 (en) Hcv fusion polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP